



**Merck & Co., Inc.
Financial Highlights Package
Fourth Quarter 2009
Table of Contents**

Definition of Terms	1
Table 1: GAAP P&L	2
Tables 2 - 3: GAAP to Non-GAAP P&L Reconciliation.....	3 - 4
Table 4: Sales - GAAP to Supplemental Combined Non-GAAP Reconciliation: 4Q and FY	5
Table 4a: Sales - U.S. / Ex- U.S. Supplemental Combined Non-GAAP	6
Table 4b: Sales - GAAP to Supplemental Combined Non-GAAP Reconciliation: 1Q-3Q	7
Table 4c: Sales - Supplemental Combined Non-GAAP: Full Year by Quarter	8
Table 5: Sales - GAAP to Supplemental Combined Non-GAAP Reconciliation: 4Q and Full Year 2008.....	9
Table 6: Equity Income / JV Sales / Other (Income) Expense.....	10

Merck & Co., Inc. Definition of Terms

GAAP ["12 + 2": 12 months of legacy Merck + 2 months of legacy Schering-Plough]

Reflects financial statements of the New Company in accordance with U.S. Generally Accepted Accounting Principles. Results include:

- Twelve Months Old Merck stand-alone results
- Schering-Plough results from the date of the merger on 11/3/09
- MSP is reflected in Equity Income 1/1/09 through the date of the merger, 11/3/09, and is fully consolidated from 11/3/09 through 12/31/09
- Average shares outstanding assuming dilution calculated using weighted average of Merck stand-alone shares through October and New Company shares for November and December
- Purchase accounting adjustments, restructuring, certain merger-related charges, the gain recorded on the MSP joint venture, and the gain on the sale of the Company's interest in the Merial joint venture with Sanofi-aventis on 9/18/09.

Non-GAAP Reconciled ["12 + 2"]

GAAP results:

- Twelve Months Old Merck stand-alone results
- Schering-Plough results from the date of the merger on 11/3/09
- MSP is reflected in Equity Income 1/1/09 through the date of the merger, 11/3/09, and is fully consolidated from 11/3/09 through 12/31/09
- Average shares outstanding assuming dilution calculated using weighted average of Merck stand-alone shares through October and New Company shares for November and December

Excluding purchase accounting, restructuring, certain merger-related costs, the gain recorded on the MSP joint venture, and the gain on the sale of the Company's interest in the Merial joint venture with Sanofi-aventis on 9/18/09.

Supplemental Combined Non-GAAP ["12 + 12"]

The Company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full quarter and full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in the applicable tables. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1

	GAAP			GAAP		
	4Q09	4Q08	% Change	Full Year 2009	Full Year 2008	% Change
Sales	\$ 10,093.5	\$ 6,032.4	67%	\$ 27,428.3	\$ 23,850.3	15%
Costs, Expenses and Other						
Materials and production ⁽¹⁾	4,900.8	1,470.0	*	9,018.9	5,582.5	62%
Marketing and administrative ⁽²⁾	3,455.2	1,862.1	86%	8,543.2	7,377.0	16%
Research and development ⁽³⁾	1,971.5	1,386.6	42%	5,845.0	4,805.3	22%
Restructuring costs ⁽⁴⁾	1,489.8	103.1	*	1,633.9	1,032.5	58%
Equity income from affiliates ⁽⁵⁾	(373.8)	(720.0)	-48%	(2,235.0)	(2,560.6)	-13%
Other (income) expense, net ⁽⁶⁾	(7,814.8)	(26.8)	*	(10,669.5)	(2,318.1)	*
Income before Taxes	6,464.8	1,957.4	*	15,291.8	9,931.7	54%
Taxes on Income	(60.0)	282.6		2,267.6	1,999.4	
Net Income	6,524.8	1,674.8	*	13,024.2	7,932.3	64%
Less: Net Income Attributable to Noncontrolling Interests	29.1	30.0		122.9	123.9	
Net Income Attributable to Merck & Co., Inc.	6,495.7	1,644.8	*	12,901.3	7,808.4	65%
Preferred Stock Dividends	2.1	-		2.1	-	
Net Income Available to Common Shareholders	\$ 6,493.6	\$ 1,644.8	*	\$ 12,899.2	\$ 7,808.4	65%
Earnings per Common Share Assuming Dilution ⁽⁷⁾	\$ 2.35	\$ 0.78	*	\$ 5.65	\$ 3.63	56%
Average Shares Outstanding Assuming Dilution	2,752.8	2,110.9		2,273.2	2,142.5	
Tax Rate ⁽⁸⁾	-0.9%	14.4%		14.8%	20.1%	

* ≥ 100%

(1) The fourth quarter and full year of 2009 include \$2.3 billion of expense for the amortization of intangible assets recognized in the Merger and the amortization of purchase accounting adjustments to inventories. Also includes restructuring costs of \$19 million and \$33 million in the fourth quarter of 2009 and 2008, respectively, and \$115 million and \$123 million for the full year of 2009 and 2008, respectively, primarily related to accelerated depreciation associated with restructuring activities.

(2) Includes merger-related costs of \$265 million and \$371 million in the fourth quarter and full year of 2009, respectively. Also includes the impact of reserving an additional \$35 million and \$62 million in the fourth quarter of 2009 and 2008, respectively, and \$75 million and \$62 million for the full year of 2009 and 2008, respectively, solely for future legal defense costs for VIOXX litigation. Additionally, reflects the impact of reserving an additional \$40 million in both full year 2009 and 2008 solely for future legal defense costs for FOSAMAX litigation.

(3) Includes restructuring costs of \$(13) million and \$97 million in the fourth quarter of 2009 and 2008, respectively, and \$232 million and \$128 million for the full year of 2009 and 2008, respectively, primarily related to accelerated depreciation associated with restructuring activities.

(4) Represents separation and other related costs, as well as gains on sales of facilities and related assets in 2008, associated with restructuring activities.

(5) Includes equity income from the Merck/Schering-Plough partnership until the Merger at which time the partnership became wholly-owned by the Company.

(6) Other (income) expense, net in the fourth quarter of 2009 reflects a gain of \$7.5 billion representing the fair value step-up of the Company's previously held interest in the Merck/Schering-Plough partnership recognized as a result of obtaining a controlling interest in the partnership in conjunction with the Merger. Other (income) expense, net in the fourth quarter of 2009 also reflects \$400 million of additional gain on the Merial divestiture which had been deferred, and merger-related costs of \$23 million. Other (income) expense, net for the full year of 2009 reflects the \$7.5 billion gain on the Merck/Schering-Plough partnership, the \$3.2 billion gain on the sale of Merck's interest in Merial Limited, \$231 million of recognized net gains in the investment portfolio, \$173 million of merger-related costs and \$92 million of charges related to the settlement of certain VIOXX litigation.

Other (income) expense, net for the full year of 2008 reflects a \$2.2 billion gain related to a distribution from AstraZeneca LP, a \$300 million expense for a contribution to The Merck Company Foundation, a \$249 million gain on the sale of the remaining worldwide rights to AGGRASTAT, \$117 million of recognized net losses in the investment portfolio and a \$58 million charge in connection with the resolution of an investigation into whether Merck violated state consumer protection laws with respect to the sales and marketing of VIOXX.

(7) On January 1, 2009, Merck adopted new guidance issued by the Financial Accounting Standards Board for computing earnings per share which requires the allocation of net income between common shareholders and participating security holders. As a result, net income available to common shareholders used to calculate earnings per common share assuming dilution was \$6,463.3 million and \$1,640.3 million for the fourth quarter of 2009 and 2008, respectively, and were \$12,853.0 million and \$7,787.6 million for the full year of 2009 and 2008, respectively.

(8) The effective tax rates for the fourth quarter and full year of 2009 reflect the impact of the gain on the Merck/Schering-Plough partnership, for which no tax provision is required, as well as the impact of purchase accounting adjustments and restructuring charges.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FOURTH QUARTER 2009
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2

	GAAP	Purchase Accounting ⁽¹⁾	Restructuring Costs ⁽²⁾	Merger-Related Costs ⁽³⁾	Certain Other Items ⁽⁴⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 10,093.5					\$ -	\$ 10,093.5
Materials and production	4,900.8	2,285.9	19.1			2,305.0	2,595.8
Marketing and administrative	3,455.2			265.0		265.0	3,190.2
Research and development	1,971.5		(12.5)			(12.5)	1,984.0
Restructuring costs	1,489.8		1,489.8			1,489.8	-
Equity income from affiliates	(373.8)					-	(373.8)
Other (income) expense, net	(7,814.8)			22.7	(7,929.5)	(7,906.8)	92.0
Income before Taxes	6,464.8	(2,285.9)	(1,496.4)	(287.7)	7,929.5	3,859.5	2,605.3
Taxes on Income	(60.0)					(458.4) ⁽⁵⁾	398.4
Net Income	6,524.8					4,317.9	2,206.9
Less: Net Income Attributable to Noncontrolling Interests	29.1					-	29.1
Net Income Attributable to Merck & Co., Inc.	6,495.7					4,317.9	2,177.8
Preferred Stock Dividends	2.1					-	2.1
Net Income Available to Common Shareholders	\$ 6,493.6					\$ 4,317.9	\$ 2,175.7
Earnings per Common Share Assuming Dilution	\$ 2.35					\$ 1.56	\$ 0.79
Average Shares Outstanding Assuming Dilution	2,752.8						2,752.8
Tax Rate	-0.9%						15.3%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Reflects the amortization of intangible assets and the amortization of inventory step-up.

(2) Amounts primarily include employee separations costs, as well as accelerated depreciation associated with facilities to be sold or closed.

(3) Merger-related costs include transaction and integration costs associated with the Merger.

(4) Included in other (income) expense is a \$7.5 billion gain representing the fair value step-up of the Company's previously held interest in the Merck/Schering-Plough partnership recognized as a result of obtaining a controlling interest in the partnership in conjunction with the Merger. Also included in other (income) expense is \$400 million of additional gain on the divestiture of Merck's interest in Merial Limited which had been deferred.

(5) Represents the estimated income tax impact on the reconciling items.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
FULL YEAR 2009
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 3

	GAAP	Purchase Accounting ⁽¹⁾	Restructuring Costs ⁽²⁾	Merger-Related Costs ⁽³⁾	Certain Other Items ⁽⁴⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 27,428.3					\$ -	\$ 27,428.3
Materials and production	9,018.9	2,285.9	115.2			2,401.1	6,617.8
Marketing and administrative	8,543.2			370.7		370.7	8,172.5
Research and development	5,845.0		231.6			231.6	5,613.4
Restructuring costs	1,633.9		1,633.9			1,633.9	-
Equity income from affiliates	(2,235.0)					-	(2,235.0)
Other (income) expense, net	(10,669.5)			173.5	(10,692.0)	(10,518.5)	(151.0)
Income before Taxes	15,291.8	(2,285.9)	(1,980.7)	(544.2)	10,692.0	5,881.2	9,410.6
Taxes on Income	2,267.6					389.6 ⁽⁵⁾	1,878.0
Net Income	13,024.2					5,491.6	7,532.6
Less: Net Income Attributable to Noncontrolling Interests	122.9					-	122.9
Net Income Attributable to Merck & Co., Inc.	12,901.3					5,491.6	7,409.7
Preferred Stock Dividends	2.1					-	2.1
Net Income Available to Common Shareholders	\$ 12,899.2					\$ 5,491.6	\$ 7,407.6
Earnings per Common Share Assuming Dilution	\$ 5.65					\$ 2.40	\$ 3.25
Average Shares Outstanding Assuming Dilution	2,273.2						2,273.2
Tax Rate	14.8%						20.0%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Reflects the amortization of intangible assets and the amortization of inventory step-up.

(2) Amounts primarily include employee separations costs, as well as accelerated depreciation associated with facilities to be sold or closed.

(3) Merger-related costs include transaction and integration costs associated with the Merger.

(4) Included in other (income) expense is a \$7.5 billion gain representing the fair value step-up of the Company's previously held interest in the Merck/Schering-Plough partnership recognized as a result of obtaining a controlling interest in the partnership in conjunction with the Merger. Also included in other (income) expense is a \$3.2 billion gain on the divestiture of Merck's interest in Merial Limited.

(5) Represents the estimated income tax impact on the reconciling items.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - GAAP TO SUPPLEMENTAL COMBINED NON-GAAP RECONCILIATION
FOURTH QUARTER AND FULL YEAR 2009
(AMOUNTS IN MILLIONS)

Table 4

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect a full quarter and full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	"3 + 3"			"12 + 12"		
	GAAP	Adjustment	Supp. Comb. Non-GAAP	GAAP	Adjustment	Supp. Comb. Non-GAAP
	4Q09	4Q09	4Q09	Full Year	Full Year	Full Year
TOTAL SALES ⁽¹⁾	\$10,093	\$2,123	\$12,216	\$27,428	\$18,537	\$45,964
HUMAN HEALTH ⁽²⁾	9,072	1,733	10,805	25,236	14,862	40,098
Bone, Resp., Imm., & Dermatology						
Singulair	1,260		1,260	4,660		4,660
Remicade	431	205	635	431	1,896	2,327
Nasonex	165	121	286	165	1,014	1,179
Fosamax	285		285	1,100		1,100
Clarinet	101	55	155	101	619	719
Propecia	123		123	440		440
Arcoxia	98		98	358		358
Asmanex	37	21	58	37	177	214
Cardiovascular						
Zetia	399	215	614	403	1,841	2,244
Vytorin	384	194	577	441	1,671	2,112
Integrilin	46	26	72	46	249	295
Diabetes & Obesity						
Januvia	558		558	1,922		1,922
Janumet	202		202	658		658
Infectious Disease						
PegIntron	149	67	216	149	696	844
Isentress	234		234	752		752
Primaxin	196		196	689		689
Cancidas	175		175	617		617
Avelox	66	52	118	66	302	368
Invanz	88		88	293		293
Rebetol	36	21	57	36	218	254
Crixivan / Stocrin	52		52	206		206
Mature Brands						
Cozaar / Hyzaar	955		955	3,561		3,561
Zocor	139		139	558		558
Claritin Rx	71	38	109	71	362	433
Vasotec / Vaseretic	85		85	311		311
Proscar	72		72	291		291
Proventil	26	30	56	26	198	225
Neurosciences & Ophthalmology						
Maxalt	156		156	575		575
Cosopt / Trusopt	134		134	503		503
Remeron	38	21	60	38	195	234
Subutex / Suboxone	36	20	56	36	175	211
Oncology						
Temodar	188	103	292	188	885	1,073
Emend	88		88	313		313
Caelyx	47	24	70	47	219	265
Intron A	38	16	54	38	192	231
Vaccines						
ProQuad, M-M-R II and Varivax	333		333	1,369		1,369
Gardasil	277		277	1,118		1,118
RotaTeq	135		135	522		522
Pneumovax	128		128	346		346
Zostavax	76		76	277		277
Women's Health & Endocrine						
Follistim/Puregon	96	53	149	96	450	546
Nuvaring	88	47	135	88	422	511
Other Human Health ⁽³⁾	781	405	1,186	1,295	3,081	4,376
ANIMAL HEALTH	494	265	759	494	2,222	2,716
CONSUMER HEALTH ⁽²⁾	149	83	232	149	1,131	1,281
Claritin OTC	39	25	63	39	367	406
Other Revenues ⁽⁴⁾	379	41	420	1,548	322	1,870

⁽¹⁾ Individual products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of >\$200M are shown. Sales reflect the then current foreign exchange rates.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Health includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of <\$200M.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The Company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - SUPPLEMENTAL COMBINED NON-GAAP
FOURTH QUARTER AND FULL YEAR 2009
(AMOUNTS IN MILLIONS)
Table 4a

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect a full quarter and full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

For a reconciliation of GAAP sales to Supplemental Combined Non-GAAP sales see Table 4.

	"3 + 3"			"12 + 12"		
	Supplemental Combined Non-GAAP			Supplemental Combined Non-GAAP		
	Global	U.S.	International	Global	U.S.	International
	4Q	4Q	4Q	Full Year	Full Year	Full Year
TOTAL SALES ⁽¹⁾	\$12,216	\$5,535	\$6,681	\$45,964	\$21,269	\$24,695
HUMAN HEALTH ⁽²⁾	10,805	4,740	6,064	40,098	17,766	22,332
Bone, Resp., Imm., & Dermatology						
Singulair	1,260	810	450	4,660	3,044	1,615
Remicade	635		635	2,327		2,327
Nasonex	286	157	129	1,179	648	530
Fosamax	285	39	246	1,100	161	939
Clarinox	155	55	100	719	249	470
Propecia	123	38	84	440	148	293
Arcoxia	98		98	358		358
Asmanex	58	55	2	214	204	10
Cardiovascular						
Zetia	614	343	271	2,244	1,296	948
Vytorin	577	319	258	2,112	1,219	893
Integrilin	72	67	5	295	275	19
Diabetes & Obesity						
Januvia	558	390	168	1,922	1,404	518
Janumet	202	136	66	658	472	187
Infectious Disease						
PegIntron	216	23	193	844	110	735
Isentress	234	113	121	752	370	382
Primaxin	196	41	155	689	136	553
Cancidas	175	19	156	617	73	543
Avelox	118	115	4	368	353	15
Invanz	88	43	45	293	152	141
Rebetol	57		57	254	1	253
Crixivan / Stocrin	52	2	50	206	10	196
Mature Brands						
Cozaar / Hyzaar	955	363	592	3,561	1,321	2,240
Zocor	139	10	129	558	45	513
Claritin Rx	109		109	433		433
Vasotec / Vaseretic	85		85	311		311
Proscar	72	2	71	291	6	285
Proventil	56	54	2	225	220	5
Neurosciences & Ophthalmology						
Maxalt	156	107	49	575	398	176
Cosopt / Trusopt	134	7	127	503	39	464
Remeron	60	3	57	234	10	224
Subutex / Suboxone	56		56	211		211
Oncology						
Temodar	292	103	189	1,073	387	686
Emend	88	55	33	313	198	115
Caelyx	70		70	265		265
Intron A	54	29	25	231	121	110
Vaccines						
ProQuad, M-M-R II and Varivax	333	310	22	1,369	1,288	81
Gardasil	277	218	59	1,118	802	317
RotaTeq	135	123	12	522	468	54
Pneumovax	128	74	54	346	245	101
Zostavax	76	76		277	277	
Women's Health & Endocrine						
Follistim / Puregon	149	45	105	546	179	368
Nuvaring	135	80	55	511	313	198
Other Human Health ⁽³⁾	1,186	318	869	4,376	1,123	3,253
ANIMAL HEALTH	759	161	598	2,716	599	2,117
CONSUMER HEALTH ⁽²⁾	232	214	19	1,281	1,175	105
Claritin OTC	63	62	1	406	390	16
Other Revenues ⁽⁴⁾	420	420		1,870	1,729	141

⁽¹⁾ Individual products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of >\$200M are shown. Sales reflect the then current foreign exchange rates.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Health includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of <\$200M.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The Company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - GAAP TO SUPPLEMENTAL COMBINED NON-GAAP RECONCILIATION
FIRST QUARTER - THIRD QUARTER 2009
(AMOUNTS IN MILLIONS)
Table 4b

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect full quarters of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

	"3 + 3"			"3 + 3"			"3 + 3"		
	GAAP	Adjustment	Supp. Comb. Non-GAAP	GAAP	Adjustment	Supp. Comb. Non-GAAP	GAAP	Adjustment	Supp. Comb. Non-GAAP
	1Q09	1Q09	1Q09	2Q09	2Q09	2Q09	3Q09	3Q09	3Q09
TOTAL SALES ⁽¹⁾	\$5,385	\$5,298	\$10,683	\$5,900	\$5,634	\$11,534	\$6,050	\$5,481	\$11,531
HUMAN HEALTH ⁽²⁾	5,019	4,215	9,235	5,470	4,488	9,956	5,676	4,425	10,101
Bone, Resp., Imm., & Dermatology									
Singular	1,057		1,057	1,257		1,257	1,085		1,085
Remicade		518	518		565	565		608	608
Nasonex		306	306		321	321		266	266
Fosamax	261		261	277		277	276		276
Clarinx		174	174		226	226		164	164
Propecia	103		103	106		106	109		109
Arcoxia	81		81	88		88	90		90
Asmanex		49	49		54	54		53	53
Cardiovascular									
Zetia	1	509	510	1	555	556	1	562	563
Vytorin	16	462	477	21	511	532	20	505	525
Integrilin		76	76		73	73		74	74
Diabetes & Obesity									
Januvia	411		411	462		462	491		491
Janumet	128		128	155		155	173		173
Infectious Disease									
PegIntron		216	216		215	215		198	198
Isentress	148		148	172		172	197		197
Primaxin	165		165	160		160	168		168
Cancidas	139		139	149		149	155		155
Avelox		109	109		71	71		70	70
Invanz	62		62	71		71	73		73
Rebetol		66	66		67	67		64	64
Crixivan / Stocrin	49		49	56		56	49		49
Mature Brands									
Cozaar / Hyzaar	839		839	906		906	861		861
Zocor	137		137	141		141	141		141
Claritin Rx		132	132		96	96		95	95
Vasotec / Vaseretic	77		77	76		76	73		73
Proscar	72		72	79		79	67		67
Proventil		54	54		56	56		59	59
Neurosciences & Ophthalmology									
Maxalt	133		133	141		141	144		144
Cosopt / Trusopt	121		121	125		125	123		123
Remeron		50	50		50	50		74	74
Subutex / Suboxone		50	50		52	52		53	53
Oncology									
Temodar		247	247		256	256		278	278
Emend	68		68	76		76	81		81
Caelyx		61	61		68	68		67	67
Intron A		54	54		67	67		56	56
Vaccines									
ProQuad, M-M-R II and Varivax	252		252	322		322	462		462
Gardasil	262		262	268		268	311		311
RotaTeq	134		134	126		126	127		127
Pneumovax	41		41	47		47	130		130
Zostavax	75		75	42		42	84		84
Women's Health & Endocrine									
Follistim / Puregon		131	131		145	145		122	122
Nuvaring		115	115		129	129		131	131
Other Human Health ⁽³⁾	185	838	1,023	146	909	1,056	183	928	1,111
ANIMAL HEALTH		621	621		672	672		664	664
CONSUMER HEALTH ⁽²⁾		384	384		381	381		283	283
Claritin OTC		149	149		108	108		85	85
Other Revenues ⁽⁴⁾	366	77	443	430	94	524	374	109	483

⁽¹⁾ Individual products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of >\$200M are shown. Sales reflect the then current foreign exchange rates.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Health includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of <\$200M.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The Company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - SUPPLEMENTAL COMBINED NON-GAAP
FULL YEAR 2009
(AMOUNTS IN MILLIONS)
Table 4c

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect full quarters and a full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.

For a reconciliation of GAAP sales to Supplemental Combined Non-GAAP sales see Tables 4 and 4b.

	2009 - Supplemental Combined Non-GAAP				
	1Q	2Q	3Q	4Q	Full Year
TOTAL SALES ⁽¹⁾	\$10,683	\$11,534	\$11,531	\$12,216	\$45,964
HUMAN HEALTH ⁽²⁾	9,235	9,956	10,101	10,805	40,098
Bone, Resp., Imm., & Dermatology					
Singulair	1,057	1,257	1,085	1,260	4,660
Remicade	518	565	608	635	2,327
Nasonex	306	321	266	286	1,179
Fosamax	261	277	276	285	1,100
Clarinox	174	226	164	155	719
Propecia	103	106	109	123	440
Arcoxia	81	88	90	98	358
Asmanex	49	54	53	58	214
Cardiovascular					
Zetia	510	556	563	614	2,244
Vytorin	477	532	525	577	2,112
Integrilin	76	73	74	72	295
Diabetes & Obesity					
Januvia	411	462	491	558	1,922
Janumet	128	155	173	202	658
Infectious Disease					
PegIntron	216	215	198	216	844
Isentress	148	172	197	234	752
Primaxin	165	160	168	196	689
Cancidas	139	149	155	175	617
Avelox	109	71	70	118	368
Invanz	62	71	73	88	293
Rebetol	66	67	64	57	254
Crixivan / Stocrin	49	56	49	52	206
Mature Brands					
Cozaar / Hyzaar	839	906	861	955	3,561
Zocor	137	141	141	139	558
Claritin Rx	132	96	95	109	433
Vasotec / Vaseretic	77	76	73	85	311
Proscar	72	79	67	72	291
Proventil	54	56	59	56	225
Neurosciences & Ophthalmology					
Maxalt	133	141	144	156	575
Cosopt / Trusopt	121	125	123	134	503
Remeron	50	50	74	60	234
Subutex / Suboxone	50	52	53	56	211
Oncology					
Temodar	247	256	278	292	1,073
Emend	68	76	81	88	313
Caelyx	61	68	67	70	265
Intron A	54	67	56	54	231
Vaccines					
ProQuad, M-M-R II and Varivax	252	322	462	333	1,369
Gardasil	262	268	311	277	1,118
RotaTeq	134	126	127	135	522
Pneumovax	41	47	130	128	346
Zostavax	75	42	84	76	277
Women's Health & Endocrine					
Follistim / Puregon	131	145	122	149	546
Nuvaring	115	129	131	135	511
Other Human Health ⁽³⁾	1,023	1,056	1,111	1,186	4,376
ANIMAL HEALTH	621	672	664	759	2,716
CONSUMER HEALTH ⁽²⁾	384	381	283	232	1,281
Claritin OTC	149	108	85	63	406
Other Revenues ⁽⁴⁾	443	524	483	420	1,870

⁽¹⁾ Individual products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of >\$200M are shown. Sales reflect the then current foreign exchange rates.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Health includes US and Canada consumer product sales.

⁽³⁾ Includes Human Health products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of <\$200M.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The Company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - GAAP TO SUPPLEMENTAL COMBINED NON-GAAP RECONCILIATION
FOURTH QUARTER AND FULL YEAR 2008
(AMOUNTS IN MILLIONS)
Table 5

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect a full quarter and full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2008.

	"3 + 3"			"12 + 12"		
	GAAP	Adjustment	Supp. Comb. Non-GAAP	GAAP	Adjustment	Supp. Comb. Non-GAAP
	4Q08	4Q08	4Q08	FY08	FY08	FY08
TOTAL SALES ⁽¹⁾	\$6,032	\$5,386	\$11,419	\$23,850	\$22,887	\$46,737
HUMAN HEALTH ⁽²⁾	5,537	4,405	9,942	22,081	18,331	40,412
Bone, Resp., Imm., & Dermatology						
Singulair	1,122		1,122	4,337		4,337
Remicade		491	491		2,118	2,118
Nasonex		280	280		1,155	1,155
Fosamax	318		318	1,553		1,553
Cardiovascular						
Zetia	2	556	558	6	2,279	2,286
Vytorin	19	548	566	84	2,339	2,424
Diabetes & Obesity						
Januvia	413		413	1,397		1,397
Janumet	120		120	351		351
Mature Brands						
Cozaar / Hyzaar	881		881	3,558		3,558
Oncology						
Temodar		242	242		1,002	1,002
Vaccines						
ProQuad, M-M-R II and Varivax	295		295	1,268		1,268
Gardasil	286		286	1,403		1,403
ANIMAL HEALTH		674	674		2,973	2,973
CONSUMER HEALTH ⁽²⁾		219	219		1,276	1,276
Other Revenues ⁽³⁾	495	88	583	1,769	308	2,077

⁽¹⁾ Individual products with annual 2009 GAAP or Supplemental Combined Non-GAAP sales of >\$1B are shown. Sales reflect the then current foreign exchange rates.

⁽²⁾ Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Health includes US and Canada consumer product sales.

⁽³⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The Company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company's product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors' understanding of the company's sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.
EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE - GAAP
FOURTH QUARTER
2009
Table 6

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	4Q09	4Q08	FY 2009	FY 2008
MERCK / SCHERING-PLOUGH ⁽¹⁾	\$ 151.0	\$ 378.1	\$ 1,195.5	\$ 1,536.3
ASTRAZENECA LP	191.7	266.8	674.3	598.4
Other ⁽²⁾	31.1	75.1	365.2	425.9
TOTAL	\$ 373.8	\$ 720.0	\$ 2,235.0	\$ 2,560.6

⁽¹⁾ Reflects equity income from the Merck/Schering-Plough partnership until the merger with Schering-Plough at which time the joint venture became wholly-owned by the Company.

⁽²⁾ Primarily reflects results for Merial Limited (until disposition on September 17, 2009), Sanofi Pasteur MSD and Johnson & Johnson^oMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

	4Q09	4Q08	Period from Jan. 1, 2009 until Sept. 17, 2009	FY 2008
Merial ⁽¹⁾				
FRONTLINE, other fipronil	\$ -	\$ 152.0	\$ 783.9	\$ 1,053.0
BIOLOGICALS	-	208.8	524.5	789.7
IVOMEK, HEARTGARD, other avermectins	-	96.8	341.4	511.8
Other Animal Health	-	67.4	199.7	288.2
TOTAL MERIAL SALES	\$ -	\$ 525.0	\$ 1,849.5	\$ 2,642.7

⁽¹⁾ On September 17, 2009, Merck sold its ownership interest in Merial Limited. Sales figures for 2009 are reported until the date of disposition.

Sanofi Pasteur MSD	4Q09	4Q08	FY 2009	FY 2008
GARDASIL	\$ 132.1	\$ 171.2	\$ 549.2	\$ 865.3
FLU VACCINES	82.3	112.7	249.4	229.9
OTHER VIRAL VACCINES	33.2	24.4	112.1	105.1
HEPATITIS VACCINES	9.5	15.9	44.2	72.6
ROTATEQ	12.7	7.2	42.2	28.4
Other Vaccines	166.5	145.2	591.5	583.5
TOTAL SANOFI PASTEUR MSD SALES	\$ 436.3	\$ 476.6	\$ 1,588.6	\$ 1,884.8

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	4Q09	4Q08	FY 2009	FY 2008
INTEREST INCOME	\$ (10.5)	\$ (147.2)	\$ (210.2)	\$ (631.4)
INTEREST EXPENSE	167.0	56.7	458.0	251.3
EXCHANGE (GAINS) LOSSES	(9.4)	73.8	(12.4)	147.4
Other, net ⁽¹⁾	(7,961.9)	(10.1)	(10,904.9)	(2,085.4)
TOTAL	\$ (7,814.8)	\$ (26.8)	\$ (10,669.5)	\$ (2,318.1)

⁽¹⁾ Other, net in 2009 primarily reflects a \$7.5 billion gain associated with the Merck/Schering-Plough partnership and a \$3.2 billion gain on the sale of Merck's ownership interest in Merial Limited. Other, net in 2008 primarily reflects a \$2.2 billion gain on distribution from AstraZeneca LP.